This is a clinical study to evaluate the potential benefits of anti-aging supplement on improvement in quality of life , biological age and other healthy outcome .

A Prospective, Multi-Center, Double-Blind, Placebo-Controlled, Randomized, Multiple- Arm, Parallel Study to evaluate the safety, tolerability, and pharmacokinetics of RNM24 in healthy adult participants - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/06/068327

Enrollment

Registered

2024-06-05

Start date

Unknown

Completion date

Unknown

Last updated

2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: RNM24: Nicotinamide food supplement, once daily for 90 days Control Intervention1: Placebo: Placebo Capsule ,once daily for 90 days

Eligibility

Inclusion criteria

Inclusion criteria: 1. Adult healthy male/females aged 40 to 65 years. 2. Participants with Body Mass Index (BMI) between 18.5 and 35 kg/m2. 3. Participants who are willing to provide written Informed Consent for participating in the study 4. Participants who are able to follow verbal and written study directions. 5. Participants must be able to maintain consistent diet and lifestyle habits throughout the study. 6. Participants must be willing to agree to use effective contraceptive methods while on treatment and for 3 months after the completion of study. 7. Participants willing to administer assigned dietary supplements for 3 months.

Exclusion criteria

Exclusion criteria: 1. Participants on current use of prescription or over-the-counter nicotinic acid. 2. Participants using any statin drugs. 3. Participants having used any tobacco product or used a recreational drug in the past 6 months. 4. Participants having abnormal screening laboratory test values or other lab test result(s) that would preclude study participation in the judgment of the investigator. 5. Participants with documented presence of atherosclerotic disease and/or cardiopulmonary disease. 6. Participants with history of drug or alcohol abuse.

Design outcomes

Primary

Measure	Time frame
1) To assess NAD+ Values in blood 2) Assessment of Biological Age 3) Physical Performance is assessed by endurance test measured on six minutes walking test 4) Change in BMI 5) Quality of Life Assessment will be done using SF-36 QuestionnaireTimepoint: Baseline to end of study.	—

Secondary

Measure	Time frame
1) Routine clinical laboratory tests: Haematology, Biochemistry, Lipid Profile, LFT, RFT parameters 2) Safety will be assessed based on number of adverse events 3) Tolerability will be assessed based on number of subjects drop out due to drug related adverse eventsTimepoint: Baseline to end of study.	—

Countries

India

Contacts

Public ContactDr Chikkalingaiah Siddegowda

Medstar Specialist Hospital

drchikkalingaiahmedstar@gmail.com9884457106

Outcome results